FDA grants accelerated approval to new treatment for advanced ovarian cancer
The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer.
-
Subscribe
Subscribe via the RSS feed